By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Blueprint Medicines 

Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a



Company News
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering 3/24/2015 6:58:28 AM
With Alexion (ALXN) Deal in Hand, Blueprint Medicines Preps for $100 Million IPO 3/24/2015 6:06:57 AM
Blueprint Medicines Appoints Charles A. Rowland, Jr. To Its Board Of Directors 3/23/2015 7:23:18 AM
Blueprint Medicines Publishes Preclinical Proof-Of-Concept Data On Promising New Therapy For Patients With Genomically Defined Hepatocellular Carcinoma 3/16/2015 7:35:42 AM
Blueprint Medicines Strikes $265 Million Deal With Alexion Pharmaceuticals Inc. (ALXN) 3/3/2015 7:26:15 AM
Blueprint Medicines Appoints Anthony Boral, M.D., Ph.D., As Senior Vice President, Clinical Development 2/11/2015 8:01:20 AM
Blueprint Medicines To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/8/2015 9:53:26 AM
Blueprint Medicines Debuts Comprehensive Preclinical Data Set On First Selective Drug For Patients With Systemic Mastocytosis At 2014 American Society of Hematology Annual Meeting 12/8/2014 8:23:14 AM
Blueprint Medicines To Present Discovery Of New Cancer Drug Targets At EORTC-National Cancer Institute-American Association for Cancer Research Symposium 11/13/2014 9:32:46 AM
MA's Blueprint Medicines Scrounges Up $50 Million 11/12/2014 6:17:25 AM